MedTek21 Announces COVID-19 Diagnostic Testing Support

April 27, 2020 – West Chester, PA – MedTek21 today announced that COVID-19 diagnostic testing is now available through the MedTek21 software and operations platform for both new and existing customers.  MedTek21 partners will now be able to order and manage these diagnostics in the same workflow as their personalized medication management and other advanced diagnostic programs.  MedTek21 has partnered with AccessDx Laboratory to ensure coast-to-coast availability of certified COVID-19 infection diagnostics, as well as IgG antibody testing, for all MedTek21 long-term care, health system, private practice, and corporate customers.

COVID-19, also known as the novel coronavirus, has been shown to be highly transmissible and presents significant danger to chronic, elderly, and other at-risk populations.  In addition to standard disease control protocol, testing and quarantine polices to minimize the spread of COVID-19 is essential amongst high-risk populations.  Multiple local, county, and state health organizations have recommended or mandated expanded testing for at-risk employees, patients, and communities.

“We are proud to have MedTek21 play a contributing a role in helping to diagnose and slow the progression of COVID-19 within highly at-risk populations,” said Dave Copas, co-founder of MedTek21.  “Our technical, operations, and laboratory partner teams have been working diligently to fast-track availability order to help our customers adequately prepare, address, and remediate the dissemination of COVID-19 within at-risk populations.”

Existing MedTek21 customers will automatically be notified via a software update of their ability to order and manage COVID-19 testing through their existing dashboards.  Any customers wishing to accelerate availability or with any additional questions on the testing program should contact their MedTek21 operations team at COVID@medtek21.com.

About MedTek21:  MedTek21 is a real-time population health and medication risk management platform that brings personalized drug-to-gene monitoring to every patient. The Company’s software-based platform works alongside existing medical record systems to continuously monitor, proactively identify, and help remediate potential medication risks. MedTek21’s mobile-based medication risk alerting, drug lookup tools, actionable reporting, and clinical support staff enable both patients and their care providers with better real-time decision making. MedTek21 is being used to positively impact outcomes and lower care costs for tens of thousands of patients across general, acute, and chronic populations. For more information on the Company, please visit www.MedTek21.com.

About AccessDx Laboratory:  AccessDX Laboratory is a CLIA-certified, CAP-accredited, and NYCQ diagnostic laboratory dedicated to providing clinical insights that improve patient outcomes.  AccessDX diagnostic solutions include pharmacogenomic (PGX) testing, cancer genomic (CGX) testing, respiratory pathogen panels, and a wide range of other clinical laboratory services.  AccessDX diagnostics are currently trusted by thousands of clinical providers in health systems nationwide.  For more information, please visit www.accessdxlab.com.

Press Inquiries:

MedTek21 COVID Hotline
covid@medtek21.com
888.380.7040